Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Holdings, Inc. reports developments for a digital health care business focused on ambulatory cardiac monitoring and arrhythmia detection. The company’s recurring updates center on the Zio ambulatory ECG portfolio, which combines patch-based monitoring, AI-powered analysis, and clinical data review to deliver cardiac rhythm insights to physicians.
Company news commonly covers quarterly and annual financial results, revenue guidance, margin trends, and operating leverage, along with clinical evidence presented at cardiology meetings. Other updates include clinician education initiatives, investor conference participation, board and governance changes, and the company’s completed transition to a holding-company structure as successor registrant to iRhythm Technologies.
Summary not available.
Summary not available.
Summary not available.
iRhythm Technologies (NASDAQ:IRTC) announced the release of its financial results for Q1 2023 on May 4, 2023, post-market close. The event will be followed by a live conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the webcast on the company’s investor relations website.
iRhythm is recognized for developing advanced digital health solutions aimed at disease detection, prevention, and prediction. Their technology integrates wearable biosensors and cloud-based analytics with proprietary algorithms to generate clinically actionable insights from cardiac data, enhancing patient care.
iRhythm Technologies, Inc. (NASDAQ:IRTC) has released its 2022 Environmental, Social, and Governance (ESG) Report, highlighting its commitment to sustainable growth. President and CEO Quentin Blackford emphasized the role of ESG initiatives in supporting the company’s mission and values. Key achievements in the report include:
- Advancing Health Equity Task Force: Established to improve access to care and address social determinants of health.
- Diversity, Equity, Inclusion, and Belonging (DEIB): Launched new initiatives leading to 48% of employees identifying as ethnically diverse.
- Climate Reporting: Disclosed 2022 greenhouse gas emissions and plans for further assessments.
The report outlines a strategic focus for ESG initiatives over the next three years, supported by formal board oversight.
iRhythm Technologies (NASDAQ: IRTC), a leader in digital health, presented transformative findings at the ACC.23/WCC conference concerning its Zio XT monitoring system. The CAMELOT study reveals Zio XT offers the highest diagnostic yield and quickest time to diagnosis for arrhythmias, alongside lower retesting and healthcare utilization rates compared to other monitors. The study analyzed Medicare data from 287,789 patients, establishing Zio XT’s superiority over Holter and other monitoring options. Other significant studies highlighted include comparisons of Zio XT to the next-generation Zio monitor, which showed improved patient comfort and performance.
iRhythm Technologies (NASDAQ: IRTC) announced the presentation of four new studies at the ACC.23/WCC conference, held from March 4-6, 2023, in New Orleans. These studies, including the significant CAMELOT study, assess the effectiveness of different cardiac monitoring services, enhancing iRhythm’s clinical evidence for its Zio products. The conference will feature key presentations, such as the real-world experience of the next-generation Zio monitor and comparative effectiveness of ambulatory monitors for arrhythmia diagnosis among Medicare beneficiaries. This research aims to improve patient outcomes and expand iRhythm's market presence.
iRhythm Technologies, Inc. (NASDAQ: IRTC) reported significant financial results for Q4 and full year 2022. Fourth quarter revenue increased by 37.7% to $112.6 million, driven by Zio XT volume and improved CMS reimbursement rates. Gross margin improved to 69.9%, while net loss narrowed to $20.2 million. For the full year, revenue grew 27.3% to $410.9 million, with a gross margin of 68.5%. However, the net loss rose to $116.2 million. For 2023, iRhythm projects revenue growth of 16% to 18%, anticipating between $475 million and $485 million. The company remains focused on operational growth and innovation.
iRhythm Technologies (NASDAQ:IRTC) is set to announce its financial results for the fourth quarter and full year 2022 on February 23, 2023, after market close. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. iRhythm is recognized for its innovative digital health solutions that utilize wearable biosensors and cloud analytics to deliver clinically actionable information. The upcoming earnings report is anticipated to provide insights into the company’s financial performance and strategic direction.
iRhythm Technologies (NASDAQ: IRTC) announced preliminary operational highlights for Q4 2022 at the J.P. Morgan Healthcare Conference. Patient registrations saw growth of over 20% year-over-year, and there was a record number of new Zio XT account openings in the U.S. The company improved its returned device rates, aligning closer to historical figures. The CMS Medicare Physician Fee Schedule for 2023 was released, providing relevant rates for reimbursement. iRhythm aims for sustainable growth in 2023 through strategic initiatives, including entering the primary care channel and launching a next-gen biosensor platform.